Biontech Stock – AstraZeneca : Vaccine panel confirms choice to delay doses up to four months in Canada
The panel is also keeping an eye on the latest reports, released Wednesday in
“We made the decision out of an abundance of caution, while further investigations were ongoing,” said Dr.
The EMA said as of
The company is “already working to understand the individual cases, epidemiology and possible mechanisms that could explain these extremely rare events.”
The EMA likewise didn’t recommend against using
“This vaccine has proven to be highly effective, it prevents severe disease and hospitalization and it is saving lives.”
The EMA said there have been some clots reported with the
More than six million Canadians have now received at least one vaccine dose and the vaccination rate is accelerating as more deliveries arrive.
Quach-Thanh said NACI still believes it is going to be better to delay second doses up to four months, instead of three or four weeks, so more people can get a first dose faster. But she said she also think that wait will be cut to between two and 2.5 months as more doses are shipped.
Deeks said the panel looked at clinical trials, “real-world evidence” of the vaccines in the general population, lab data and modelling that showed a single dose could significantly reduce deaths and hospitalizations from COVID-19. Vaccine science also typically shows immune responses improve if the wait between doses is longer, she said.
“NACI’s expert opinion also considered that within a global pandemic setting, reducing the risk of severe disease outcomes in the majority of the population, and decreasing transmission in the community will have the greatest public health impact,” Deeks said.
This report by
© 2021 The Canadian Press. All rights reserved., source